Prelude Therapeutics
PRLD
68 hedge funds and large institutions have $235M invested in Prelude Therapeutics in 2022 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 19 increasing their positions, 25 reducing their positions, and 19 closing their positions.
7,500% more call options, than puts
Call options by funds: $1.52M | Put options by funds: $20K
9% less funds holding
Funds holding: 75 → 68 (-7)
24% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 25
26.6% less ownership
Funds ownership: 98.22% → 71.61% (-27%)
37% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 19
46% less capital invested
Capital invested by funds: $438M → $235M (-$202M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
+$8.31M |
| 2 |
BlackRock
New York
|
+$1.42M |
| 3 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
+$560K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$519K |
| 5 |
IA
IndexIQ Advisors
New York
|
+$519K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.19M |
| 2 |
Millennium Management
New York
|
-$3.7M |
| 3 |
Morgan Stanley
New York
|
-$2.74M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.62M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$1.45M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SFI
76
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
| – | -$273K | -21,900 | Closed |
|
|
ECM
77
ExodusPoint Capital Management
New York
| – | -$259K | -20,773 | Closed |
|
|
NFGH
78
Nan Fung Group Holdings
Kai Tak,
Hong Kong
| – | -$253K | -20,350 | Closed |
|
|
TI
79
Trexquant Investment
Stamford,
Connecticut
| – | -$242K | -19,458 | Closed |
|
|
PL
80
Parkwood LLC
Cleveland,
Ohio
| – | -$158K | -12,667 | Closed |
|
81
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
| – | -$157K | -12,594 | Closed |
|
82
Jane Street
New York
| – | -$128K | -10,241 | Closed |
|
|
QT
83
Quantbot Technologies
New York
| – | -$102K | -8,200 | Closed |
|
|
PHK
84
Point72 Hong Kong
Hong Kong
| – | -$48K | -3,872 | Closed |
|
|
SOW
85
State of Wyoming
Cheyenne,
Wyoming
| – | -$7K | -544 | Closed |
|
|
CG
86
Cutler Group
San Francisco,
California
| – | +$915 | +100 | New |
|
PRLD Hedge Fund Activity: Q1 2022 in Review
68 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q1 2022, worth a combined $235M — down 46% from $438M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of PRLD and 12 opened new positions — a net loss of 7 holders — while 25 trimmed existing stakes and 19 added.
The largest buyer was UBS AM, adding an estimated $8.31M. The largest seller was Fidelity Investments, cutting an estimated $5.19M.
- 68 institutional investors held Prelude Therapeutics (PRLD) as of Q1 2022, down from 75 in Q4 2021.
- Funds reported $235M of Prelude Therapeutics stock for Q1 2022, down 46% quarter-over-quarter.
- 12 funds opened new Prelude Therapeutics positions in Q1 2022 and 19 closed out, a net change of -7 holders.
- The largest Prelude Therapeutics buyer in Q1 2022 was UBS AM, an estimated $8.31M added.
- The largest Prelude Therapeutics seller in Q1 2022 was Fidelity Investments, an estimated $5.19M sold.
Based on aggregated 13F filings for Q1 2022.